glp-1 kidney outcomes news Renal effects of receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future | Endocrine Kidney Outcomes With Glucagon-Like Peptide-1

When the Breakthrough Obesity G-Agonist Drugs Exceed Expectations The expanding GLP-1 family of drugs and their expanded potential use cases Back last December I wrote about the The New Obesity Breakthrough Drugs, and specifically the striking results in randomized trials for semaglutide (Wegovy) and tirzepatide (Mounjaro) for weight loss, their putative mechanism(s), while also emphasizing their very high cost, lack of plan for successful weaning, and exacerbation of health inequities

Weight fluctuates daily due to water retention, food volume, and hormonal cycles, so weekly averages provide better data than daily numbers

Was it randomized and controlled

Thickened or discoloured nails Beyond pitting, many people also notice that their nails start becoming darker, thicker, or slightly separated from the skin beneath